Cargando…

Improved Survival after Breast-Conserving Therapy Compared with Mastectomy in Stage I-IIA Breast Cancer

SIMPLE SUMMARY: The majority of patients with breast cancer are suitable for either breast-conserving therapy, consisting of breast-conserving surgery and radiation therapy, or mastectomy alone. In the present study, we compared survival outcomes in 1360 patients affected with early-stage breast can...

Descripción completa

Detalles Bibliográficos
Autores principales: Ratosa, Ivica, Plavc, Gaber, Pislar, Nina, Zagar, Tina, Perhavec, Andraz, Franco, Pierfrancesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8393026/
https://www.ncbi.nlm.nih.gov/pubmed/34439197
http://dx.doi.org/10.3390/cancers13164044
_version_ 1783743638695575552
author Ratosa, Ivica
Plavc, Gaber
Pislar, Nina
Zagar, Tina
Perhavec, Andraz
Franco, Pierfrancesco
author_facet Ratosa, Ivica
Plavc, Gaber
Pislar, Nina
Zagar, Tina
Perhavec, Andraz
Franco, Pierfrancesco
author_sort Ratosa, Ivica
collection PubMed
description SIMPLE SUMMARY: The majority of patients with breast cancer are suitable for either breast-conserving therapy, consisting of breast-conserving surgery and radiation therapy, or mastectomy alone. In the present study, we compared survival outcomes in 1360 patients affected with early-stage breast cancer (stage I-IIA) according to the type of local treatment. We confirmed that patients treated with breast-conserving therapy had a lower rate of local, regional, and distant disease recurrences, and at least equivalent overall survival compared to those treated with mastectomy alone. Our results add to previous research showing a potential benefit of breast-conserving therapy when compared to mastectomy in patients suitable for both treatments at baseline. ABSTRACT: In the current study, we sought to compare survival outcomes after breast-conserving therapy (BCT) or mastectomy alone in patients with stage I-IIA breast cancer, whose tumors are typically suitable for both locoregional treatments. The study cohort consisted of 1360 patients with stage I-IIA (T1–2N0 or T0–1N1) breast cancer diagnosed between 2001 and 2013 and treated with either BCT (n = 1021, 75.1%) or mastectomy alone (n = 339, 24.9%). Median follow-ups for disease-free survival (DFS) and overall survival (OS) were 6.9 years (range, 0.3–15.9) and 7.5 years (range, 0.2–25.9), respectively. Fifteen (1.1%), 14 (1.0%) and 48 (3.5%) patients experienced local, regional, and distant relapse, respectively. For the whole cohort of patients, the estimated 5-year DFS and OS were 96% and 97%, respectively. After stratification based on the type of local treatment, the estimated 5-year DFS for BCT was 97%, while it was 91% (p < 0.001) for mastectomy-only treatment. Inverse probability of treatment weighting matching based on confounding confirmed that mastectomy was associated with worse DFS (HR 2.839, 95% CI 1.760–4.579, p < 0.0001), but not with OS (HR 1.455, 95% CI 0.844–2.511, p = 0.177). In our study, BCT was shown to have improved disease-specific outcomes compared to mastectomy alone, emphasizing the important role of adjuvant treatments, including postoperative radiation therapy, in patients with early-stage breast cancer at diagnosis.
format Online
Article
Text
id pubmed-8393026
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-83930262021-08-28 Improved Survival after Breast-Conserving Therapy Compared with Mastectomy in Stage I-IIA Breast Cancer Ratosa, Ivica Plavc, Gaber Pislar, Nina Zagar, Tina Perhavec, Andraz Franco, Pierfrancesco Cancers (Basel) Article SIMPLE SUMMARY: The majority of patients with breast cancer are suitable for either breast-conserving therapy, consisting of breast-conserving surgery and radiation therapy, or mastectomy alone. In the present study, we compared survival outcomes in 1360 patients affected with early-stage breast cancer (stage I-IIA) according to the type of local treatment. We confirmed that patients treated with breast-conserving therapy had a lower rate of local, regional, and distant disease recurrences, and at least equivalent overall survival compared to those treated with mastectomy alone. Our results add to previous research showing a potential benefit of breast-conserving therapy when compared to mastectomy in patients suitable for both treatments at baseline. ABSTRACT: In the current study, we sought to compare survival outcomes after breast-conserving therapy (BCT) or mastectomy alone in patients with stage I-IIA breast cancer, whose tumors are typically suitable for both locoregional treatments. The study cohort consisted of 1360 patients with stage I-IIA (T1–2N0 or T0–1N1) breast cancer diagnosed between 2001 and 2013 and treated with either BCT (n = 1021, 75.1%) or mastectomy alone (n = 339, 24.9%). Median follow-ups for disease-free survival (DFS) and overall survival (OS) were 6.9 years (range, 0.3–15.9) and 7.5 years (range, 0.2–25.9), respectively. Fifteen (1.1%), 14 (1.0%) and 48 (3.5%) patients experienced local, regional, and distant relapse, respectively. For the whole cohort of patients, the estimated 5-year DFS and OS were 96% and 97%, respectively. After stratification based on the type of local treatment, the estimated 5-year DFS for BCT was 97%, while it was 91% (p < 0.001) for mastectomy-only treatment. Inverse probability of treatment weighting matching based on confounding confirmed that mastectomy was associated with worse DFS (HR 2.839, 95% CI 1.760–4.579, p < 0.0001), but not with OS (HR 1.455, 95% CI 0.844–2.511, p = 0.177). In our study, BCT was shown to have improved disease-specific outcomes compared to mastectomy alone, emphasizing the important role of adjuvant treatments, including postoperative radiation therapy, in patients with early-stage breast cancer at diagnosis. MDPI 2021-08-11 /pmc/articles/PMC8393026/ /pubmed/34439197 http://dx.doi.org/10.3390/cancers13164044 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ratosa, Ivica
Plavc, Gaber
Pislar, Nina
Zagar, Tina
Perhavec, Andraz
Franco, Pierfrancesco
Improved Survival after Breast-Conserving Therapy Compared with Mastectomy in Stage I-IIA Breast Cancer
title Improved Survival after Breast-Conserving Therapy Compared with Mastectomy in Stage I-IIA Breast Cancer
title_full Improved Survival after Breast-Conserving Therapy Compared with Mastectomy in Stage I-IIA Breast Cancer
title_fullStr Improved Survival after Breast-Conserving Therapy Compared with Mastectomy in Stage I-IIA Breast Cancer
title_full_unstemmed Improved Survival after Breast-Conserving Therapy Compared with Mastectomy in Stage I-IIA Breast Cancer
title_short Improved Survival after Breast-Conserving Therapy Compared with Mastectomy in Stage I-IIA Breast Cancer
title_sort improved survival after breast-conserving therapy compared with mastectomy in stage i-iia breast cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8393026/
https://www.ncbi.nlm.nih.gov/pubmed/34439197
http://dx.doi.org/10.3390/cancers13164044
work_keys_str_mv AT ratosaivica improvedsurvivalafterbreastconservingtherapycomparedwithmastectomyinstageiiiabreastcancer
AT plavcgaber improvedsurvivalafterbreastconservingtherapycomparedwithmastectomyinstageiiiabreastcancer
AT pislarnina improvedsurvivalafterbreastconservingtherapycomparedwithmastectomyinstageiiiabreastcancer
AT zagartina improvedsurvivalafterbreastconservingtherapycomparedwithmastectomyinstageiiiabreastcancer
AT perhavecandraz improvedsurvivalafterbreastconservingtherapycomparedwithmastectomyinstageiiiabreastcancer
AT francopierfrancesco improvedsurvivalafterbreastconservingtherapycomparedwithmastectomyinstageiiiabreastcancer